KSU veterinary researchers, Anivive license FIP antiviral drugSeptember 20, 2018A collaboration at Kansas State University and Anivive Lifesciences is promoting the commercial development of GC376, an antiviral compound for feline infectious peritonitis (FIP), which previously has had no effective treatment or cure. Yunjeong Kim, DVM, PhD, ACVM, and Kyeong-Ok "KC" Chang, DVM, MS, PhD, virologists at KSU's College of Veterinary Medicine, and William Groutas, a medicinal chemist at Wichita State University, have been collaborating since 2006 to develop antiviral drugs for human and animal viruses. The licensing agreement was coordinated by the KSU Institute for Commercialization with Anivive Lifesciences, a California company whose proprietary software accelerates the discovery and development process of new pet medicines. "We have been working on antiviral drugs that inhibit a specific virus protease of some important human and animal viruses, and we were able to make very potent inhibitors of FIP," Dr. Kim said. "Through collaborative work with Niels Pedersen at the University of California, Davis—including a field trial on feline patients—we became increasingly hopeful that antiviral treatment may one day substantially benefit cats with FIP. Licensing our compound to Anivive Lifesciences is a huge step forward in transitioning our research to commercialization to make this treatment available to the …
SPONSORED CONTENTProtect your patients from the start.Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) is the first monthly preventative of its kind. Combining three ingredients for month-long protection. + Learn more
